Article
EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3/Slug signaling.
Cellular signalling - 1 Apr 2022
Shen Jiwei, Meng Yuting, Wang Kunlun, Gao Minghuan, Du Jianan, Wang Junfang, Li Zengqiang, Zuo Daiying, Wu Yingliang
Abstract excerpt
The echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion gene occurs in approximately 5% of non-small-cell lung cancers (NSCLCs). The development of ALK tyrosine kinase inhibitors (ALK-TKIs) is a major advance in treating NSCLC with the ALK fusion gene. Nevertheless, acquired resistance to ALK-TKIs ultimately limits their use. A prevalent mechanism of drug resistance in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.